Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection

Mandon, Elodie Desuzinges; Pizzorno, Andrés; Traversier, Aurélien; Champagne, Anne; Hamelin, Marie‐Ève; Lina, Bruno; Boivin, Guy; Dejean, Emmanuel; Rosa‐Calatrava, Manuel; Jawhari, Anass

doi:10.1016/j.vaccine.2019.10.018

Cited by 12 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The integrity of hemagglutinin proteins was evaluated by SDS-PAGE analysis and intrinsic tryptophan fluorescence spectrometry. The integrity of hemagglutin proteins in the AS01 B /FluzoneQuad powder was further evaluated by a standard hemagglutination (HA) assay using chicken red blood erythrocytes as previously described [48]. Briefly, 50 µ L of the reconstituted vaccine powder was two-fold serially diluted using PBS (10 mM, pH 7.2) in U-bottom 96-well plates (Corning Inc., Corning NY).…”

Section: Methodsmentioning

confidence: 99%

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying

AboulFotouh

Williams

et al. 2022

Preprint

View full text Add to dashboard Cite

AS01B is a liposomal formulation of two immunostimulants namely 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and QS-21. The liposomal formulation of AS01B reduces the endotoxicity of MPL and the lytic activity of QS-21; however, it renders the adjuvant sensitive to accidental slow freezing. The liposomal formulation also represents a major challenge towards the formulation of dry powders of vaccines containing AS01B. In the present study, we tested the feasibility of applying thin-film freeze-drying (TFFD) to engineer dry powders of the AS01B liposomal adjuvant alone or vaccines containing AS01B as an adjuvant. Initially, we showed that after the AS01B liposomal adjuvant was subjected to TFFD using sucrose as a stabilizer at 4% w/v, the particle size distribution of AS01B liposomes reconstituted from the dry powder was identical to the liquid adjuvant before drying. We then showed using ovalbumin (OVA) as a model antigen adjuvanted with AS01B (AS01B/OVA) that subjecting the AS01B/OVA vaccine to TFFD and subsequent reconstitution did not negatively affect the AS01B liposome integrity, nor the immunogenicity of the vaccine. Importantly, the thin-film freeze-dried vaccine was not sensitive to repeated freezing-and-thawing. Finally, the feasibility of using TFFD to prepare dry powders of AS01B-adjuvanted vaccines was further confirmed using AS01B-adjuvanted Fluzone Quadrivalent and Shingrix, which contains AS01B. It is concluded that the TFFD technology can enable the formulation of AS01B-adjuvanted vaccines as freezing-insensitive dry powders in single-vial presentation.

show abstract

Section: Methodsmentioning

confidence: 99%

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying

AboulFotouh

Williams

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Calix[ n ]arenes (CX n ) (Figure a) are cyclic oligomers with a chalice shape synthesized via condensation of phenols and formaldehyde . They are the third generation of supramolecular hosts after crown ethers and cyclodextrins and are considered to have low biological toxicity . The discovery journey of these compounds first began with the synthesis of unidentified cyclic oligomers in Zincke’s lab.…”

Section: Introductionmentioning

confidence: 99%

“…1 They are the third generation of supramolecular hosts after crown ethers and cyclodextrins and are considered to have low biological toxicity. 2 The discovery journey of these compounds first began with the synthesis of unidentified cyclic oligomers in Zincke's lab. By 1944, several investigators proposed cyclic structures for the tetramers, including Zincke.…”

Section: Introductionmentioning

confidence: 99%

Porous Polycalix[n]arenes as Environmental Pollutant Removers

Abubakar

Škorjanc

Shetty

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

A new and innovative class of calixarene-based polymers emerged as adsorbents for a variety of compounds and ions in solution and vapor media. These materials take advantage of the modifiable rims and hydrophobic cavities of the calixarene monomers, in addition to the porous nature of the polymeric matrix. With main-chain calixarenes' function as supramolecular hosts and the polymers' high surface areas, polycalixarenes can effectively encapsulate target analytes. This feature is particularly useful for environmental remediation as dangerous and toxic molecules reversibly bind to the macrocyclic cavity, which facilitates their removal and enables repeated use of the polymeric sorbent. This Spotlight touches on the unique characteristics of the calixarene monomers and discusses the synthetic methods of our reported calixarene-based porous polymers, including Sonogashira−Hagihara coupling, and diazo and imine bond formation. It then discusses the promising applications of these materials in adsorbing dyes, micropollutants, iodine, mercury, paraquat, and perfluorooctanoic acid (PFOA) from water. In most cases, these reports cover materials that outperform others in terms of recyclability, rates of adsorption, or uptake capacities of specific pollutants. Finally, this Spotlight addresses the current challenges and future aspects of utilizing porous polymers in pollution treatment.

show abstract

“…The integrity of the HA proteins in the TFFD powders was evaluated using a standard hemagglutination assay using chicken red blood erythrocytes as previously described [31]. Briefly, vaccine powders were reconstituted in water, and then 50 µL sample was 2-fold serially diluted using phosphate buffered saline (PBS, 10 mM, pH 7.2) in U-bottom 96-well plates.…”

Section: Characterization Of Addavax-adjuvanted Influenza Vaccine and Fluad Quadrivalent Vaccine Powdersmentioning

confidence: 99%

Formulation of Dry Powders of Vaccines Containing MF59 or AddaVax by Thin-Film Freeze-Drying

AboulFotouh

Uno

et al. 2021

Preprint

View full text Add to dashboard Cite

Oil-in-water (O/W) nanoemulsion-based vaccine adjuvants such as MF59® are often used in seasonal and pandemic influenza vaccines. However, vaccines containing nanoemulsions require cold chain for storage and are sensitive to accidental freezing. We explored the feasibility of developing dry powders of vaccines adjuvanted with MF59 or AddaVax™, a preclinical grade nanoemulsion that has the same composition and droplet size as MF59, by thin-film freeze-drying (TFFD). AddaVax alone was successfully converted from a liquid to dry powders by TFFD using trehalose as a stabilizing agent while maintaining the droplet size distribution of the AddaVax when reconstituted, whereas subjecting the same AddaVax composition to conventional shelf freeze-drying led to significant aggregation or fusion. TFFD was then applied to convert liquid AddaVax-adjuvanted vaccines containing either model antigens such as ovalbumin and lysozyme, mono-, bi-, and tri-valent recombinant hemagglutinin (rHA) protein-based H1 and/or H3 (universal) influenza vaccine candidates, as well as the MF59-containing Fluad® Quadrivalent influenza vaccine to dry powders. Antigens, stabilizing agents, and buffer showed different effects on the physical properties of the vaccines (e.g., mean particle size and particle size distribution) after subjected to TFFD, but the integrity and hemagglutination activity of the rHA antigens did not significantly change and the immunogenicity of reconstituted influenza vaccine candidates was preserved when evaluated in BALB/c mice. The vaccine dry powder was not sensititve to repeated freezing-and-thawing, in contrast to its liquid counterpart. It is concluded that TFFD can be applied to convert vaccines containing MF59 or an nanoemulsion with the same composition and droplet size as MF59 from liquid to dry powders while maintaining the immunogencity of the vaccines, and it may be used to prepare dry powders of multivalent universal influenza vaccines.

show abstract

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection

Cited by 12 publications

References 30 publications

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying

Porous Polycalix[n]arenes as Environmental Pollutant Removers

Formulation of Dry Powders of Vaccines Containing MF59 or AddaVax by Thin-Film Freeze-Drying

Contact Info

Product

Resources

About

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection

Cited by 12 publications

References 30 publications

Development of Dry Powder Formulations of AS01Bcontaining vaccines using Thin-Film Freeze-Drying

Development of Dry Powder Formulations of AS01Bcontaining vaccines using Thin-Film Freeze-Drying

Porous Polycalix[n]arenes as Environmental Pollutant Removers

Formulation of Dry Powders of Vaccines Containing MF59 or AddaVax by Thin-Film Freeze-Drying

Contact Info

Product

Resources

About

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying

Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying